Akbar K. Waljee, MD, MSc

home / authors / akbar-k-waljee-md-msc

Articles

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

March 8th 2023

Distinct Health Care Use Patterns of Patients With Chronic Gastrointestinal Diseases

Shirley Cohen-Mekelburg, MD, MS Liberty Greene, MS, MEd Jeffrey Berinstein, MD, MS Akbar K. Waljee, MD, MSc Timothy P. Hofer, MD, MS Sameer D. Saini, MD, MS Donna M. Zulman, MD, MS

Patients with complex chronic disease can be grouped by varying propensity for health care continuity patterns, which could be harnessed to personalize health care utilization interventions.

October 7th 2019

Inflammatory Bowel Disease Readmissions Are Associated With Utilization and Comorbidity

Shirley Cohen-Mekelburg, MD, MS Russell Rosenblatt, MD, MS Beth Wallace, MD, MS Nicole Shen, MD, MS Brett Fortune, MD, MSc Akbar K. Waljee, MD, MSc Sameer Saini, MD, MS Ellen Scherl, MD Robert Burakoff, MD Mark Unruh, PhD

Thirty-day readmissions related to inflammatory bowel disease are common and associated with longer length of stay and a higher likelihood of having an associated comorbid condition compared with index hospitalizations.

December 6th 2018

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts

Shail M. Govani, MD, MSc Rachel Lipson, MSc Mohamed Noureldin, MBBS, MSc Wyndy Wiitala, PhD Peter D.R. Higgins, MD, PhD, MSc Sameer D. Saini, MD, MSc Jacqueline A. Pugh, MD Dawn I. Velligan, PhD Ryan W. Stidham, MD, MSc Akbar K. Waljee, MD, MSc

Veterans with inflammatory bowel disease taking adalimumab appear to be more likely to remain on the drug 1 year after initiation than patients who are privately insured.